BCG vaccination provides protection against IAV but not SARS-CoV-2 Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Since the vast majority of species solely rely on innate immunity for host defense, it stands to reason that a critical evolutionary trait like immunological memory evolved in this primitive branch of our immune system. There is ample evidence that vaccines such as bacillus Calmette-Guérin (BCG) induce protective innate immune memory responses (trained immunity) against heterologous pathogens. Here we show that while BCG vaccination significantly reduces morbidity and mortality against influenza A virus (IAV), it fails to provide protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In contrast to IAV, SARS-CoV-2 infection leads to unique pulmonary vasculature damage facilitating viral dissemination to other organs, including the bone marrow (BM), a central site for BCG-mediated trained immunity. Finally, monocytes from BCG-vaccinated individuals mount an efficient cytokine response to IAV infection, while this response is minimal following SARS-CoV-2. Collectively, our data suggest that the protective capacity of BCG vaccination is contingent on viral pathogenesis and tissue tropism.

authors

  • Kaufmann, Eva
  • Khan, Nargis
  • Tran, Kim A
  • Ulndreaj, Antigona
  • Pernet, Erwan
  • Fontes, Ghislaine
  • Lupien, Andréanne
  • Desmeules, Patrice
  • McIntosh, Fiona
  • Abow, Amina
  • Moorlag, Simone JCFM
  • Debisarun, Priya
  • Mossman, Karen
  • Banerjee, Arinjay
  • Karo-Atar, Danielle
  • Sadeghi, Mina
  • Mubareka, Samira
  • Vinh, Donald C
  • King, Irah L
  • Robbins, Clinton S
  • Behr, Marcel A
  • Netea, Mihai G
  • Joubert, Philippe
  • Divangahi, Maziar

publication date

  • March 2022